In this issue, CEO Karin Bryder is interviewed on several current themes for the company: public procurements and marketing in Sweden, the expansion in Europe with planned launches in Germany and the UK in Q4 2019 and the company’s ongoing evaluation of new potential products in addition to efemia.

To read the newsletter, and subscribe to receive upcoming issues, follow this link:

http://bit.ly/inventocten

The newsletter is published in Swedish and English, with a flexible publishing frequency based on Invent Medic’s news flow. It is produced together with the company’s IR communication partner Honeybadger, www.honeybadger.se. Invent Medic encourages feedback and requests on topics for upcoming issues of the newsletter.

For more information please contact
Karin Bryder, CEO
Phone: +46 (0)723811710
E-mail: info@inventmedic.com

About Invent Medic
Invent Medic Sweden AB (Invent Medic) is a Swedish company developing innovative products with the aim to improve women’s health and quality of life. The company’s products are to be safe, effective and easy to use. The finished women’s health products are sold through the company’s Arcamea brand. Invent Medic’s first product, Efemia, is a CE-certified and patented medical technology product used to reduce stress urinary incontinence (SUI) that was shown to reduce urine leakage with 77 percent during usage in a clinical study. The product is based on the same scientific principle as the TVT method, the premier surgical treatment for SUI. Invent Medic’s share is listed on the Spotlight Stock Market with the ticker symbol IMS, and the share’s ISIN code is SE0007603402. More information can be found at www.inventmedic.com and www.spotlightstockmarket.com.